Join the Psoriasis group to help and get support from people like you.
Psoriasis News
Related terms: Erythrodermic Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Palmo-plantar Psoriasis, Psoriasis vulgaris, Pustular Psoriasis
N-NAIL Score More Accurate Than NAPSI for Diagnosing Nail Psoriasis
WEDNESDAY, Aug. 27, 2025 – Both the Nail Psoriasis Severity Index (NAPSI) and the Nijmegen-Nail Psoriasis Activity Index Tool (N-NAIL) provide accurate cutoffs for diagnosing nail psoriasis, with...
Youthful Immunity: A Double-Edged Sword for Seniors
FRIDAY, Aug. 15, 2025 — The Fountain of Youth may not be all it’s cracked up to be, researchers say. A genetic “fountain of youth” actually might increase seniors’ risk of developing autoimmune diseas...
Subclinical Synovitis Risk Higher in Psoriasis Without Musculoskeletal Involvement
TUESDAY, July 22, 2025 – Subclinical synovitis is significantly more common among patients with psoriasis without musculoskeletal involvement than healthy controls, according to a review published...
Psoriasis 101: Causes, Symptoms and Treatments, Explained
MONDAY, July 7, 2025 — Psoriasis is a chronic autoimmune condition that mainly affects the skin. When you have psoriasis, your immune system sends signals to your skin cells to grow too fast. N...
Central Adiposity Measures Associated With Psoriasis Risk
TUESDAY, June 3, 2025 – Central adiposity measures are strongly associated with psoriasis risk, with a stronger association in women, according to a research letter published online May 27 in the...
Psoriasis Tied to Increased Risk for Sleep Disorders
MONDAY, June 2, 2025 – Both mild and moderate-to-severe psoriasis are significantly associated with an increased risk for sleep disorders, according to a study published online May 13 in JEADV ...
FDA Approves Starjemza (ustekinumab-hmny), a Biosimilar to Stelara
Guangzhou and London – May 27, 2025 – Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma Pharm...
Belly Fat Linked To Psoriasis
THURSDAY, May 29, 2025 — Belly flab appears to be a stronger warning sign for psoriasis than fat located elsewhere on the body, a new study says. Fat around the abdomen is more strongly linked to p...
FDA Approves Topical Foam for Plaque Psoriasis of the Scalp and Body, Zoryve
TUESDAY, May 27, 2025 – The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque psoriasis of the scalp and body in adult and...
Residual Inflammation Seen in One-Third of Patients With Psoriasis on Biologics
WEDNESDAY, May 21, 2025 – For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity...
Psoriatic Arthritis Tied to Delays in Diagnosis Compared With Rheumatoid Arthritis
WEDNESDAY, April 30, 2025 – Patients with psoriatic arthritis (PsA) have delays in diagnosis compared with those with rheumatoid arthritis (RA), according to a study published online March 29 in...
Flares Occur Frequently in Generalized Pustular Psoriasis
WEDNESDAY, April 16, 2025 – Patients with generalized pustular psoriasis (GPP) experience frequent flares, and treatment alterations of off-label agents are frequently observed, according to a study...
Real-World Study Shows Effectiveness of Ixekizumab for Psoriasis
FRIDAY, Feb. 28, 2025 – For patients with moderate-to-severe plaque psoriasis, ixekizumab is effective and safe, with induction therapy enhancing initial response, according to a study published...
Childhood Maltreatment May Up Risk for Immune-Mediated Inflammatory Disorders
THURSDAY, Jan. 23, 2025 – On a global scale, childhood maltreatment is associated with a higher risk for developing some immune-mediated inflammatory disorders (IMIDs), according to a study...
FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar to Stelara
JERSEY CITY, N.J., Dec. 17, 2024 – Celltrion announced today that the U.S. Food and Drug Administration (FDA) has approved Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), for...
Further information
Related condition support groups
Plaque Psoriasis, Dermatological Disorders
Related drug support groups
prednisone, methylprednisolone, methotrexate, Humira, triamcinolone, clobetasol, fluocinonide, prednisolone, Remicade, view more... Stelara, Otezla, Cosentyx, Skyrizi, dexamethasone, adalimumab, etanercept, desonide, halobetasol, Taltz, ustekinumab, Cimzia, Therapeutic, Tremfya, Ilumya